Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | ESR1 | P03372 | 1/20 | 0.64 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.64 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | GGT1 | P19440 | 1/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338852 | 0.95 | HSD17B10 (0.63) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL29669847 | 0.91 | HSD17B10 (0.71) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL789771 | 0.91 | HSD17B10 (0.71) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL14674298 | 0.89 | KDM4E (0.56) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL6948356 | 0.88 | SLC6A3 (0.72) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL14972 | 0.86 | HSD17B10 (0.69) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL14674824 | 0.85 | KDM4E (0.52) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL13537487 | 0.84 | KMT2A (0.67) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL789772 | 0.83 | HSD17B10 (0.61) | KDM4EHSD17B10LMNACYP1A2CYP2C9 | |
| SCHEMBL446340 | 0.83 | SLC6A3 (0.60) | KDM4ELMNATSHRALDH1A1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113406242-A | Detection method of aspirin-related substances | 江苏万珺医药科技有限公司 | 2021-09-17 | — | — | CN | claimed |
| WO-2023137518-A1 | PLATINUM COMPLEXES | Western Sydney University (AU) | 2023-07-27 | — | — | WO | disclosed |
| CN-113214587-B | Transparent, antibacterial organic glass and its manufacturing method | 浙江华帅特新材料科技有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-113406242-A | Detection method of aspirin-related substances | 江苏万珺医药科技有限公司 | 2021-09-17 | — | — | CN | disclosed |
| CN-113214587-A | Transparent, antibacterial organic glass and its manufacturing method | 浙江华帅特新材料科技有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-07-06 | — | — | US | disclosed |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIV GEORGIA (US) | 2016-11-10 | — | — | US | disclosed |
| EP-3080137-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | The University Of Georgia Research Foundation, Inc (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9351980-B2 | Di-aspirin derivatives | THE UNIVERSITY OF WOLVERHAMPTON (GB) | 2016-05-31 | — | — | US | disclosed |
| WO-2015089389-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2015-06-18 | — | — | WO | disclosed |
| US-20130035317-A1 | Di-Aspirin Derivatives | THE UNIVERISTY OF WOLVERHAMPTON (GB) | 2013-02-07 | — | — | US | disclosed |
| WO-2011098839-A2 | DI-ASPIRIN DERIVATIVES | THE UNIVERSITY OF WOLVERHAMPTON (GB) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190726-A9 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | KDM4E 3915/4885HSD17B10 3107/4885LMNA 4674/4885 |
| US-20160326200-A1 | PRODRUG FOR RELEASE OF CISPLATIN AND CYCLOOXYGENASE INHIBITOR | PTGS1, PTGES, PTGIS | KDM4E 3915/4885HSD17B10 3107/4885LMNA 4674/4885 |
| US-20130035317-A1 | Di-Aspirin Derivatives | SDHA, DLD, DPYD | KDM4E 2764/4885HSD17B10 987/4885LMNA 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.